ZSCAN30 Knockout cell line (SU-DHL-1)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

ZSCAN30 (zinc finger and SCAN domain containing 30) encodes a zinc finger protein predicted to function as a sequence-specific transcription factor for RNA polymerase II-dependent gene regulation. The protein is predicted to bind DNA within transcriptional regulatory regions and to function in the nucleus. These characteristics indicate a potential role in transcriptional control, although the specific target genes, molecular mechanisms, and biological processes regulated by ZSCAN30 remain incompletely characterized.

The SU-DHL-1 cell line was established in 1973 from the pleural effusion of a 10-year-old male patient. Originally diagnosed as diffuse histiocytic lymphoma, the tumor was subsequently reclassified as diffuse large cell lymphoma and later as malignant histiocytosis. According to the REAL/WHO classification, the cell line represents anaplastic large cell lymphoma (ALCL) and carries the t(2;5)(p23;q35) translocation resulting in an NPM1-ALK (NPM-ALK) fusion gene. SU-DHL-1 is used as a model for studying ALCL biology and ALK-associated oncogenic signaling.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.